论文部分内容阅读
目的 :研究缓解后维持强化阶段用大剂量阿糖胞苷 (HD Ara C)化疗对延长急性髓细胞白血病 (AML)患者无病生存期(DFS)的疗效。方法 :治疗组在常规化疗的基础上 ,用HD Ara C 1～ 2 g/m2 ,q12h ,持续 3h以上静脉输注 ,第 1、3、5天使用 ,每年 1～2次 ,连用 3年。对照组仅常规化疗。比较两组的DFS。结果 :治疗组DFS( 1年、3年、5年 )较对照组明显延长 ,差异有显著性 (P<0 0 1)。结论 :HD Ara C用于AML缓解后的维持强化治疗疗效较好 ,是延长患者的DFS的有效措施之一。HD Ara C有一定的毒副作用 ,但可以加强支持治疗 ,避免死亡发生
OBJECTIVE: To investigate the efficacy of high-dose HD Ara C chemotherapy for prolonging disease-free survival (DFS) in patients with acute myeloid leukemia (AML) after intensive maintenance phase of remission. Methods: The treatment group on the basis of conventional chemotherapy, with HD Ara C 1 ~ 2 g / m2, q12h, continuous infusion of more than 3h, the first 1,3,5 days, 1 or 2 times per year, once every 3 years. Control group only conventional chemotherapy. DFS was compared between the two groups. Results: The DFS (1 year, 3 years and 5 years) in the treatment group was significantly longer than that in the control group (P <0.01). Conclusion: HD Ara C is effective in maintaining intensive therapy after remission of AML and is one of the effective measures to prolong DFS in patients. HD Ara C has some toxic side effects, but can enhance supportive care and avoid death